PARGY-LAD
propargyllysergic acid diethylamide
Viewing r1 — May 12, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
PARGY-LAD (6-propargyl-6-nor-LSD) is a semi-synthetic psychedelic of the lysergamide class. It is a reduced-potency structural analog of LSD, requiring roughly three to four times the dose for comparable intensity. It activates serotonin receptors in the cortex, disrupting normal sensory filtering and producing the visual and cognitive shifts characteristic of classical psychedelics.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, mescaline +3 moreLSD, psilocybin, mescaline, DMT, AL-LAD, ETH-LAD show less
Synthesized in 1985 by Andrew Hoffman in David Nichols's laboratory as part of a systematic study of LSD analogs,[2] PARGY-LAD received limited human testing by Alexander Shulgin, documented in TiHKAL (1997).[3] Its only commercial appearance — a brief 2014 grey-market offering — was found to contain other compounds rather than PARGY-LAD itself.[4] PARGY-LAD has never entered clinical trials and remains largely unavailable today.
Subjective effects include geometric visual patterns, time alteration, altered conceptual thinking, ego dissolution, and mood shifts. The experience is qualitatively similar to LSD — a broad shift in perception and thought — but arrives at higher doses and resolves somewhat sooner.[3][5] Anxiety, thought loops, and residual stimulation are characteristic unwanted effects from the lysergamide class.
PARGY-LAD does not produce physical dependence, and rapid tolerance after a single dose makes compulsive use self-limiting.[6] The primary danger is psychological — anxiety, paranoia, and disorientation scaling with dose — compounded by the near-impossibility of verifying that any sample labeled PARGY-LAD is authentic. No receptor binding data, pharmacokinetic studies, or clinical trials exist; the entire human evidence base is one qualitative report.[3]
History[edit]
Discovery
PARGY-LAD was first synthesized in 1985 by Andrew Hoffman, working in David Nichols's laboratory.[2] It was designed alongside AL-LAD and ETH-LAD to study how structural changes at a specific nitrogen position affect psychedelic potency. Alexander Shulgin later tested it in humans, documenting threshold effects near 160 µg and full activity near 500 µg in TiHKAL (1997).[3]
Research chemical market
PARGY-LAD appeared briefly on the grey market in September 2014.[4] A tested sample was found to contain AL-LAD and LSZ rather than the labeled compound.[4] The vendor withdrew it shortly after, and most reports from this period cannot be reliably attributed to PARGY-LAD.
Present status
PARGY-LAD has never entered clinical trials and remains one of the least characterized lysergamides to have reached human use. The published record extends only to the 1985 synthesis paper and Shulgin's qualitative notes.
The name "PARGY-LAD" follows the same abbreviation pattern as AL-LAD and ETH-LAD — the N6 substituent prefix (propargyl, shortened to PARGY) followed by LAD (lysergic acid diethylamide).
Chemistry[edit]
Structure
PARGY-LAD belongs to the lysergamide family, built on the ergoline ring system shared by LSD and related compounds. Its defining feature is a propargyl group — a three-carbon chain ending in a carbon–carbon triple bond — attached at the N6 nitrogen. This small structural change reduces potency relative to both LSD and AL-LAD.[3]
Molecular properties
| Molecular formula | C₂₂H₂₅N₃O |
| Molecular weight | 347.5 g/mol |
Its molecular formula is C₂₂H₂₅N₃O (347.5 g/mol) — two carbons heavier than LSD.[7] The molecule has a specific three-dimensional shape required for activity; only one mirror-image orientation binds psychedelic-relevant receptors[7][1] — the opposite arrangement is pharmacologically inert. No melting point, solubility, or stability data have been published for PARGY-LAD.
Pharmacology[edit]
Mechanism of action
No direct receptor data have been published for PARGY-LAD. As a lysergamide, it is presumed to activate serotonin receptors on cortical neurons,[1] disrupting the brain's normal sensory filtering and producing the psychedelic state.[8] This mechanism has been confirmed for LSD through receptor-blocking experiments and structural biology.[9][8]
Secondary targets — serotonin, dopamine, and adrenergic receptors — are inferred from lysergamide class pharmacology.[10][11] PARGY-LAD's specific affinities at these targets are unknown. Unlike stimulants, it does not act by blocking neurotransmitter reuptake.[12]
Pharmacokinetics
No pharmacokinetic data exist for PARGY-LAD. For reference, LSD lasts far longer than its blood half-life because it becomes physically trapped inside the serotonin receptor[13][9] — a mechanism that may help explain PARGY-LAD's shorter reported duration. Liver enzymes CYP1A2 and CYP3A4 are the presumed metabolizers, by analogy with related compounds.[14]
Neuroscience[edit]
Where it acts
No neuroimaging data exist for PARGY-LAD. Based on its presumed serotonin receptor activation, it is expected to act on deep-layer neurons of the prefrontal cortex — the same targets as LSD.[1] In LSD studies, this activation dissolves boundaries between brain networks and is thought to underlie ego dissolution and heightened sensory perception.
Why it matters
Serotonergic psychedelics promote new neuronal connections — increased branching and new synaptic growth — through growth factor signaling.citation needed Recent research has shown that N6 modifications can separate a lysergamide's hallucinogenic potency from its ability to promote this kind of brain rewiring.[15]
The leading theoretical framework proposes that serotonin receptor activation loosens the brain's established predictions, allowing raw sensory input greater influence over conscious experience.citation needed If PARGY-LAD achieves meaningful receptor activation at its active doses, this predicts a qualitatively similar but attenuated effect compared to LSD.
- Does PARGY-LAD achieve sufficient receptor occupancy at human-active doses (275–500 µg) to produce the same pattern of network-level brain changes seen with LSD, or does its reduced potency yield qualitatively different neural effects?
- Does the propargyl modification alter which intracellular signaling pathways are activated at 5-HT₂A, potentially changing the balance between hallucinogenic and neuroplasticity-promoting effects?
- Is the shorter duration attributable to faster receptor dissociation, weaker lid trapping, or distinct metabolic clearance?
Subjective Effects[edit]
The experience unfolds as a broad shift in perception and thought — visual patterns emerge, time warps, and the sense of a fixed self loosens. The overall quality is LSD-like: an encompassing psychedelic state rather than a narrowly visual or narrowly cognitive one. Set and setting powerfully shape its emotional direction.[3][5]
Compared to LSD, PARGY-LAD is less potent and resolves somewhat sooner, most closely paralleling AL-LAD in character.[3] Whether the propargyl modification creates qualitative differences beyond potency reduction remains unknown. The confirmed adulteration of 2014 commercial samples means most available community reports cannot be reliably attributed to PARGY-LAD.[4]
Effect Grid
At 275–500 µg oral, clear psychedelic effects are present. Visual geometry becomes distinct — patterning on surfaces, color alteration, object transformations, and visual drifting are reliably produced. Symmetrical texture repetition and perspective distortion emerge. Internal hallucinations may appear with eyes closed. Music enhancement is pronounced.
Conceptual thinking, introspection enhancement, and thought connectivity become prominent cognitive features. Time alteration is noticeable — minutes may feel stretched or compressed. Novelty enhancement colors the perceptual field. Emotional enhancement can swing between euphoria and anxiety depending on set and setting.
Body load increases: nausea during the come-up, moderate muscle tension, vasoconstriction, and temperature dysregulation are common. Pupil dilation is evident. Appetite suppression is marked. Sleep is difficult for 6+ hours. Shulgin's "full activity" dose of approximately 500 µg falls at the upper boundary of this tier.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Geometry · Visual breathing · Auditory enhancement · Brightness alteration · Tracers · Perspective distortion · Environmental patterning · Light sensitivity · Sound sensitivity · Visual morphing · Ganzfeld effect · Holotropic state · After-images · Symmetrical texture repetition · Depth perception distortion · Visual diffraction · Auditory misinterpretation · Peripheral vision distortion · Spatial disorientation · Touch enhancement · Synesthesia · Visual acuity enhancement · Proprioceptive distortion · Auditory distortion · Peripheral misidentification · Vestibular distortion · Visual haze / noise · Visual melting · Olfactory enhancement · Visual processing acceleration · Visual magnification · Taste enhancement · Touch suppression · Tinnitus · Flashbacks · Object transformations · Internal hallucinations · Environmental orbism / cubism · External hallucinations · Object activation · Visual recursion · Auditory hallucinations · Perspective hallucinations · Olfactory hallucination · Persisting hallucinations
Tracers · Perspective distortion · Environmental patterning · Light sensitivity · Sound sensitivity · Visual morphing · Ganzfeld effect · Holotropic state · After-images · Symmetrical texture repetition · Depth perception distortion · Visual diffraction · Auditory misinterpretation · Peripheral vision distortion · Spatial disorientation · Touch enhancement · Synesthesia · Visual acuity enhancement · Proprioceptive distortion · Auditory distortion · Peripheral misidentification · Vestibular distortion · Visual haze / noise · Visual melting · Olfactory enhancement · Visual processing acceleration · Visual magnification · Taste enhancement · Touch suppression · Tinnitus · Flashbacks · Object transformations · Internal hallucinations · Environmental orbism / cubism · External hallucinations · Object activation · Visual recursion · Auditory hallucinations · Perspective hallucinations · Olfactory hallucination · Persisting hallucinations
Wakefulness · Spontaneous body sensations · Appetite suppression · Body high · Insomnia · Tingling / electric sensations · Nausea · Muscle tension · Laughter fits · Physical fatigue · Restlessness · Heart rate perception changes · Vibrations / buzzing · Headache · Excessive sweating · Tactile euphoria · Motor control impairment · Dehydration sensation · Bodily lightness · Body schema distortion · Dizziness · Dry mouth · Abnormal heartbeat · Watery eyes · Nystagmus (eye wobbles) · Sexual arousal enhancement · Involuntary body movements · Bodily pressures · Breathing alteration · Trembling · Yawning · Increased urination · Bruxism · Vomiting · Motor control enhancement · Seizure threshold reduction · Bodily dissociation · Tactile hallucination
Body high · Insomnia · Tingling / electric sensations · Nausea · Muscle tension · Laughter fits · Physical fatigue · Restlessness · Heart rate perception changes · Vibrations / buzzing · Headache · Excessive sweating · Tactile euphoria · Dehydration sensation · Bodily lightness · Body schema distortion · Dizziness · Dry mouth · Abnormal heartbeat · Watery eyes · Nystagmus (eye wobbles) · Sexual arousal enhancement · Involuntary body movements · Bodily pressures · Breathing alteration · Trembling · Yawning · Increased urination · Bruxism · Vomiting · Motor control enhancement · Seizure threshold reduction · Bodily dissociation · Tactile hallucination
Thought connectivity · Aesthetic enhancement · Cognitive flexibility · Openness enhancement · Immersion enhancement · Thought acceleration · Pattern recognition enhancement · Cognitive euphoria · Creativity enhancement · Thought loops · Increased nature relatedness · Multiple thought streams · Humor enhancement · Memory suppression · Confusion · Analysis enhancement · Cognitive fatigue · Cognitive impairment · Synchronicity · Information processing enhancement · Language suppression · Cognitive dysphoria · Memory fragmentation · Thought disorganization · Focus enhancement · Motivation enhancement
Immersion enhancement · Thought acceleration · Pattern recognition enhancement · Cognitive euphoria · Creativity enhancement · Thought loops · Increased nature relatedness · Multiple thought streams · Humor enhancement · Memory suppression · Confusion · Analysis enhancement · Cognitive fatigue · Cognitive impairment · Synchronicity · Information processing enhancement · Language suppression · Cognitive dysphoria · Memory fragmentation · Thought disorganization · Focus enhancement · Motivation enhancement
Simultaneous emotions · Anxiety · Catharsis · Dysphoria
Disinhibition · Sociability enhancement · Trust enhancement · Communication enhancement · Flow state · Communication suppression · Boundary dissolution · Ego dissolution · Identity alteration · Cognitive disconnection
Flow state · Communication suppression · Boundary dissolution · Ego dissolution · Identity alteration · Cognitive disconnection
Time cessation
Non-dual awareness · Death-rebirth sequence · Entity contact
Recursive awareness
Timeline
First alerts emerge — mild stimulation, possible slight nausea, and a sense of anticipatory awareness. Perceptual changes are subliminal or absent.
Progressive intensification of perceptual changes. Visual drifting, color enhancement, and building body sensations develop. Cognitive shifts become identifiable.
Full psychedelic effects — visual geometry, conceptual thinking, emotional intensification, and maximum perceptual changes. Time alteration is most pronounced.
Gradual reduction in visual and cognitive intensity. Residual perceptual effects persist. Mood often shifts toward reflective or contemplative.
Subtle residual effects — mild mood elevation or fatigue, slight perceptual sensitivity, possible insomnia. Cognitive baseline gradually returns.
⚠ Avoid driving or operating heavy machinery for at least 12 hours after ingestion.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
No controlled toxicity data exist for PARGY-LAD, and the toxic dose is unknown.safety citation needed Lysergamides as a class have wide margins between psychoactive and lethal doses — no human death has been attributed directly to the pharmacological effects of LSD.[1]
Class-level acute adverse effects include raised blood pressure, rapid heart rate, elevated body temperature, and — rarely — heart rhythm disturbances, most often in the context of polydrug use.safety citation needed The documented adulteration of 2014 samples[4] means any adverse reports from that period cannot be reliably attributed to this compound.
Psychological risks
Acute risks include panic, severe anxiety, paranoia, and thought disorganization.[1] In predisposed individuals, use can trigger psychotic episodes.
Rarely, lasting visual disturbances and perceptual abnormalities — HPPD (HPPD) — can persist long after the experience ends.[16] Risk factors include pre-existing anxiety, prior HPPD episodes, tinnitus, and existing visual disturbances.[17] Prevention and treatment approaches have been reviewed by Doyle et al.[18]
Tolerance and dependence
Tolerance builds rapidly after a single dose — serotonin receptors in the cortex downregulate within 24 hours, producing full cross-tolerance with LSD, psilocybin, mescaline, and DMT.[6] Community estimates place the tolerance half-life at roughly 6 days and full reset at roughly 14 days.[5]
PARGY-LAD does not produce physical dependence and is not reinforcing in the way stimulants or opioids are. Compulsive use is rare.[1][12]
Drug interactions
Tramadol — dangerous
Tramadol raises serotonin levels by blocking its reuptake.[19] Combining this with PARGY-LAD's serotonin receptor activation can overload the serotonin system — producing agitation, muscle rigidity, rapid heart rate, and dangerous overheating.[20]safety citation needed
MAOIs — severe risk
Monoamine oxidase inhibitors block the enzyme that breaks down serotonin.[19] Combining an MAOI with any serotonergic psychedelic can drive serotonin to life-threatening levels.safety citation needed
Lithium
Combining lithium with classical psychedelics has been associated with seizure risk in case reports.safety citation needed
Cannabis — unknown
No data exist on PARGY-LAD combined with cannabis. Cannabis can intensify and prolong psychedelic experiences, sometimes precipitating anxiety or paranoia.
CYP-mediated interactions
Based on the metabolic pathway inferred from AL-LAD and ETH-LAD,[14] strong inhibitors of CYP1A2 (fluvoxamine, ciprofloxacin) or CYP3A4 (ketoconazole, ritonavir) may raise PARGY-LAD levels. Inducers (rifampicin, carbamazepine) may lower them. These interactions are theoretical.inferred
Contraindications
Absolute contraindications:
- Personal or family history of psychotic spectrum disorders (schizophrenia, schizoaffective disorder, bipolar I with psychotic features): serotonin receptor activation can trigger psychotic episodes in predisposed individuals[1]
- Concurrent MAOI use: severe serotonin syndrome risk[19]
- Concurrent tramadol use: serotonin toxicity via dual serotonergic mechanism[20]
- Concurrent lithium use: seizure risk documented with classical psychedelicssafety citation needed
Relative contraindications:
- Heart conditions or uncontrolled high blood pressure: lysergamides produce transient vasoconstriction and rapid heart ratesafety citation needed
- Prior HPPD episodes or predisposing factors (anxiety disorders, pre-existing visual disturbances, tinnitus)[17]
- Pregnancy or breastfeeding: no safety data exist for any lysergamide in human pregnancysafety citation needed
- Severe liver impairment: if metabolism proceeds via CYP1A2/CYP3A4 as with structural analogs, impaired liver function may significantly alter clearance[14]
Harm Reduction[edit]
Forms & Identification
The only tested commercial sample of PARGY-LAD — from a 2014 grey-market batch — was found to contain AL-LAD and LSZ, not PARGY-LAD.[4] Standard Ehrlich and Hofmann reagent tests confirm the presence of a lysergamide but cannot distinguish between individual ones. Only laboratory analysis — mass spectrometry or NMR — can verify identity.
Given the documented adulteration history and extreme rarity of authentic material, any sample labeled PARGY-LAD warrants elevated skepticism. A positive reagent test confirms a lysergamide is present; it does not confirm PARGY-LAD specifically.
Guidelines
- Test all material with Ehrlich reagent at minimum — a negative result rules out lysergamides entirely
- Start at the low end of reported dose ranges and wait at least two hours before considering redosing
- Have a sober, trusted companion present who understands psychedelic crisis support
- Prepare the physical environment in advance: comfortable seating, controlled lighting, water, light food, and a quiet space to retreat to
- Avoid dosing on an empty stomach to reduce nausea; a light meal 1–2 hours beforehand is preferable
- Clear the schedule for the full day — effects may persist 6–8 hours with additional residual stimulation
Set & Setting
Environment and mental state powerfully shape the psychedelic experience. A familiar, comfortable space and a stable emotional baseline reduce the likelihood of acute anxiety or panic.
A trusted, sober companion is particularly advisable given PARGY-LAD's minimal characterization. Even experienced psychedelic users are operating with less verified information than usual.
Aftercare & integration. The days following a psychedelic experience often carry residual emotional sensitivity and altered perspective. Journaling within 24–48 hours helps preserve insights before they fade. Discussing the experience with a trusted person — a friend, therapist, or integration circle — supports processing.
If distressing material surfaced, support from a therapist familiar with psychedelic experiences is advisable. Persistent visual disturbances, anxiety, or depersonalization lasting more than a few days warrant clinical attention — these may indicate early HPPD or related conditions.
Recovery & Support
Classical psychedelics rarely produce compulsive use patterns, and PARGY-LAD's rapid tolerance development makes sustained daily use pharmacologically self-limiting. If psychedelic use has become a pattern of avoidance or is causing functional impairment, peer support organizations such as the Fireside Project (62-FIRESIDE) and MAPS integration resources offer non-judgmental assistance.
For individuals whose psychedelic experiences have triggered or worsened mental health conditions, clinical care from a psychiatrist familiar with substance-induced disorders is the appropriate next step.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most difficult psychedelic experiences are distressing but not medically dangerous. Seek immediate help if any of the following occur: self-harm attempts or expressed intent, complete disconnection from reality with inability to communicate, seizures, chest pain, or loss of consciousness.
Immediate steps:
- 1. Move the person to a quiet, safe space with minimal stimulation
- 2. Speak calmly and reassuringly — do not argue with or contradict their experience
- 3. Do not physically restrain unless there is immediate danger of self-harm
- 4. If symptoms are purely psychological (anxiety, confusion, fear), maintain calm presence and wait
- 5. Call emergency services if physical symptoms appear (seizure, chest pain, unresponsiveness) or if psychological distress includes active self-harm risk
What to tell the dispatcher: State the substance name and approximate dose if known, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect callers who report drug-related emergencies from prosecution.
Legal Status[edit]
PARGY-LAD is not specifically scheduled by name under international drug control conventions or most national controlled substance schedules, but its structural relationship to LSD means it falls under structural analog provisions or blanket psychoactive substance legislation in many jurisdictions.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not explicitly scheduled; subject to Federal Analogue Act | As a structural analog of LSD (Schedule I), PARGY-LAD is treated as Schedule I under 21 U.S.C. § 813 if intended for human consumption. Prosecution requires demonstrating substantially similar structure and pharmacology — both criteria met given the lysergamide scaffold and LSD-like discriminative stimulus properties.[2] |
| United Kingdom | Controlled under Psychoactive Substances Act 2016 | Blanket ban on psychoactive substances except specifically exempt categories (alcohol, tobacco, caffeine, licensed medicines). Production, supply, and possession with intent to supply are criminal offenses. |
| Germany | Controlled under Neue-psychoaktive-Stoffe-Gesetz (NpSG) | Effective July 18, 2019. Production, import, and supply for placement on the market are punishable offenses. |
| Australia | Presumptively Schedule 9 (Prohibited Substance) | May qualify as an LSD structural analog under the Therapeutic Goods Act. Explicit scheduling not confirmed.citation needed |
| Canada | Not explicitly scheduled | Not listed under the Controlled Drugs and Substances Act. May be subject to analog provisions if marketed for human use.citation needed |
| International | Not scheduled | Not listed under UN Convention on Psychotropic Substances schedules. Not named in any international treaty instrument. |
Legal status varies by jurisdiction and changes frequently. This information is not legal advice.
references
- [1]
- [2] ^abcHoffman A, Nichols DE (1985) Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives — Journal of Medicinal Chemistry doi:10.1021/jm00147a022
- [3]
- [4]
- [5]
- [6] ^abde la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, Gonzalez-Maeso J (2022) Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice — ACS Chemical Neuroscience doi:10.1021/acschemneuro.2c00170